Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bisphosphonates Labels Should Discuss Duration Of Use, Advisory Panels Conclude

This article was originally published in The Pink Sheet Daily

Executive Summary

But members of FDA's Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committees acknowledged the lack of definitive evidence on potential risks from long-term use of the osteoporosis drugs.

You may also be interested in...



Odanacatib Phase III Success Suggests Merck’s Primary Care Gamble Is Paying Off

A data monitoring committee’s early termination of a 16,000-patient Phase III study of Merck’s cap-K inhibitor odanacatib suggests the osteoporosis therapy could have a competitive profile. Drug will need to offer significant advantages to cut it in the crowded market already saturated with generics.

Odanacatib Phase III Success Suggests Merck’s Primary Care Gamble Is Paying Off

A data monitoring committee’s early termination of a 16,000-patient Phase III study of Merck’s cap-K inhibitor odanacatib suggests the osteoporosis therapy could have a competitive profile. The drug will need to offer significant advantages to cut it in the crowded market already saturated with generics.

Drug Safety Business: Start-Up With AERS Filter Eyes Bisphosphonate Events

A small start-up company has developed a technique to filter the data in FDA’s Adverse Events Reporting System (AERS) database, which it says provides a more accurate analysis of adverse event reports.

Topics

UsernamePublicRestriction

Register

PS072866

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel